Trazodone - a new antidepressant
1981; Elsevier BV; Volume: 28; Issue: 22 Linguagem: Inglês
10.1016/0024-3205(81)90586-5
ISSN1879-0631
AutoresM.M. Al-Yassiri, S. I. Ankier, P. K. Bridges,
Tópico(s)Neurotransmitter Receptor Influence on Behavior
ResumoTrazodone is a new antidepressant of current interest with a chemical structure unrelated to other available antidepressant agents. Both animal and human biopharmacological studies indicate a profile of activity which is not typical of either tricyclic or MAOI antidepressants. Although trazodone blocks the re-uptake of 5-HT into serotoninergic neurones it is also a potent central antagonist of 5-HT. Recent studies have shown that trazodone reduces the sensitivity of central β-adrenoreceptors by an as yet undefined mechanism. However, the relationship between the known pharmacology of trazodone and its clinical activity remains unclear. Clinical data on various depressive states show that trazodone has an activity equivalent in potency to available medication. Trazodone is well absorbed and high blood concentrations occur within 1 – 2 hours. The quality of side effects and adverse reactions reported by various authors confirm that it is a comparatively safe drug in use. In particular it lacks both anticholinergic activity and adverse cardiotoxic effects.
Referência(s)